Zivo Safety Study Accepted for Publication in Toxicology Journal, Allows Company to Proceed with GRAS Review Panel for Market Approval

Zivo Safety Study Accepted for Publication in Toxicology Journal, Allows Company to Proceed with GRAS Review Panel for Market Approval

KEEGO HARBOR, MI / ACCESSWIRE / September 20, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) abiotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that Toxicology Reports, a peer-reviewed scientific journal, has accepted the Company's safety testing manuscript for publication. This is a necessary step in meeting compliance requirements for GRAS (Generally Recognized As Safe) affirmation and subsequent market entry.With the acceptance in hand, ZIVO can now move forward with a GRAS science panel review, the last regulatory step before ZIVO can commence sale of its algal biomass as a human food ingredient.

The GRAS science panel is composed of food safety and food science academics and industry specialists. ZIVO has already supplied a considerable portfolio of test data and analytics to members of the panel. This last step of publishing study findings officially kicks off the review and acceptance of product data compiled over the last two-plus years. ZIVO Director of R&D Dr. Amy Steffek and VP-R&D William Pfund spearheaded the multidisciplinary program that is required in order to allow ZIVO to market a unique, proprietary form of microalgae in the US and other countries that recognize the GRAS affirmation process. Typically, the review and affirmation process is concluded within 30 days' time once the panel is officially convened.

If the GRAS affirmation is obtained, ZIVO may begin generating revenue from the sale of its property algal biomass directly to food manufacturers and marketers. One such proposed marketer is NutriChipz, formed by health food entrepreneur Richard Galdi, which has executed a licensing agreement with ZIVO Bioscience and is in the process of developing a unique algae-based snack food. Mr. Galdi is the founder of 3 Zero's, a successful brand of zero-fat, zero-carb, zero-calorie salad dressings, which he sold to an East Coast food distributor in 2017. He has now turned his attention to healthy snacks and chips.

In turn, ZIVO principals are continuously recruiting contract growers globally to meet anticipated demand for its dried algal biomass, granting production agreements to established growers that can meet the Company's quality and safety standards.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.


Investor Relations
(248) 452 9866 ext 150
ZIVO Bioscience, Inc.

SOURCE: Zivo Bioscience, Inc.